Sartorius Ag · XETR:SRT
Sartorius — Q1 2026 Earnings Presentation
20 slides from Sartorius's earnings presentation, Apr 23, 2026
Slide 1: Investor Conference Call Q1 2026 Results
Investor Conference Call Q1 2026 Results Michael Grosse, Florian Funck, René Fáber Sartorius | Sartorius Stedim Biotech | April 23, 2026
Slide 2: Agenda
Agenda Sartorius Group Q1 2026 results | FY 2026 outlook Sartorius Stedim Biotech Group Q1 2026 results | FY 2026 outlook Questions & Answers 2
Slide 3: Q1 marks positive start to 2026
Sartorius Group Q1 marks positive start to 2026 Group ▪ Substantial sales revenue growth; robust growth contribution of consumables in both divisions ▪ Resilient ul EBITDA margin despite tariff headwinds and investments in future growth initiatives ▪ Strong free cash flow development; continued dele
Slide 4: High customer interest underscores relevance of Sartorius’ innovations across biologics development and manufacturing
High customer interest underscores relevance of Sartorius’ innovations across biologics development and manufacturing More efficient cell therapy More efficient cell line development manufacturing Genetically engineered Eveo Cell Therapy Platform CellCelector CLD CHO host cell line Automated, multi-
Slide 5: Substantial sales growth driven by continued consumables strength
Sartorius Group Substantial sales growth driven by continued consumables strength Sartorius Group Bioprocess Solutions Lab Products & Services Sales revenue | € in millions Sales revenue | € in millions Sales revenue | € in millions +7.5% cc | +1.8% +8.1% cc | +2.4% +4.9% cc | -0.6% 883 899 718 735
Slide 6: All regions contribute positively to business development
Sartorius Group All regions contribute positively to business development EMEA Americas Asia | Pacific Sales revenue | € in millions Sales revenue | € in millions Sales revenue | € in millions +8.0% cc +6.0% cc +8.9% cc 364 392 321 308 198 199 Q1 2025 Q1 2026 Q1 2025 Q1 2026 Q1 2025 Q1 2026 ▪ BPS: S
Slide 7: Continued solid profitability
Sartorius Group Continued solid profitability Sartorius Group Bioprocess Solutions Lab Products & Services Ul. EBITDA & margin | Ul. EBITDA & margin | Ul. EBITDA & margin | € in millions € in millions € in millions +1.6% +3.4% -9.0% 29.8% 29.7% 31.8% 31.5% 263 267 226 233 22.6% 20.7% 37 34 Q1 2025 Q
Slide 8: Sound cash flow development
Sartorius Group Sound cash flow development Sartorius Group Q1 2025 Q1 2026 in % € in millions Underlying net profit1,2 85 83 -1.9 ▪ Underlying net profit reflects higher depreciation for capacity expansion Underlying EPS (ord.) 1.22 1.20 -2.0 ▪ Reported net profit increased strongly, driven by FX e
Slide 9: Deleveraging ongoing; commitment to investment-grade rating unchanged
Sartorius Group Deleveraging ongoing; commitment to investment-grade rating unchanged Key financial indicators Net debt and net debt to underlying EBITDA 6.0 Sartorius Group Dec. 31, Mar. 31, 5,000 € in millions unless otherwise specified 2025 2026 5.0 4,000 4.0 Equity ratio in % 39.8 39.4 3,000 3.0
Slide 10: 2026 guidance confirmed
Sartorius Group 2026 guidance confirmed Guidance 2026 Sartorius Group Bioprocess Solutions Lab Products & Services Sales revenue growth1 ~5% to ~9% ~6% to ~10% ~2% to ~6% Underlying EBITDA margin Slightly above 30% Slightly above 32% Slightly below 21% ▪ Group sales growth includes ~1pp contribution
Slide 11: Agenda
Agenda Sartorius Group Q1 2026 results | FY 2026 outlook Sartorius Stedim Biotech Group Q1 2026 results | FY 2026 outlook Questions & Answers 11
Slide 12: Substantial sales growth and resilient margin
Sartorius Stedim Biotech Group Substantial sales growth and resilient margin Sales revenue | € in millions Ul. EBITDA & margin | € in millions +7.9% cc | +2.3% +1.9% 745 762 30.7% 30.8% 233 229 Q1 2025 Q1 2026 Q1 2025 Q1 2026 ▪ Continued strong recurring business; equipment business showed expected
Slide 13: All regions contribute positively to business development
Sartorius Stedim Biotech Group All regions contribute positively to business development EMEA Americas Asia | Pacific Sales revenue | € in millions Sales revenue | € in millions Sales revenue | € in millions +9.1% cc +5.6% cc +9.4% cc 338 311 274 261 160 162 Q1 2025 Q1 2026 Q1 2025 Q1 2026 Q1 2025 Q
Slide 14: Sound cash flow development
Sartorius Stedim Biotech Group Sound cash flow development Sartorius Stedim Biotech Q1 2025 Q1 2026 in % € in millions Underlying net profit1,2 113 114 +0.5 ▪ Underlying net profit reflects higher depreciation for capacity expansion Underlying EPS 1.16 1.17 +0.5 ▪ Reported net profit up, driven by F
Slide 15: Strong balance sheet; deleveraging ongoing
Sartorius Stedim Biotech Group Strong balance sheet; deleveraging ongoing Key financial indicators Net debt and net debt to underlying EBITDA 4,000 6.0 Sartorius Stedim Biotech Dec. 31, Mar. 31, 5.0 € in millions unless otherwise specified 2025 2026 3,000 4.0 Equity ratio in % 51.7 50.6 2,000 3.0 2.
Slide 16: 2026 guidance confirmed
Sartorius Stedim Biotech Group 2026 guidance confirmed Guidance 2026 Sales revenue growth1 Underlying EBITDA margin Sartorius Stedim Biotech Group ~6% to ~10% Slightly above 31% ▪ Sales growth includes ~1pp contribution from US tariff-related surcharges For financial modelling on SSB level ▪ Capex r
Slide 17: Questions & Answers
17 Questions & Answers SRTOULS SARTORI
Slide 18: Contacts and Financial calendar
Contacts and Financial calendar May 19, 2026 RBC Global Healthcare Conference, New York May 21, 2026 Petra Müller Berenberg Roadshow, Luxembourg May 26, 2026 Head of Investor Relations dbAccess European Champions Conference, Frankfurt +49.551.308.6035 May 28, 2026 petra.mueller2@sartorius.com Jeffer
Slide 19: Disclaimer
Disclaimer This presentation contains statements concerning the future performance of the Sartorius and the Sartorius Stedim Biotech Groups. These statements are based on assumptions and estimates. Although we are convinced that these forward-looking statements are realistic, we cannot guarantee tha
Slide 20: Simplifying Progress
Simplifying Progress